Yaso Therapeutics is a pharmaceutical startup dedicated to addressing unmet needs in the fields of anti-infectives and contraception. The company is particularly focused on developing innovative antiviral solutions for the treatment and prevention of herpes simplex viruses (HSV1 and HSV2). Their flagship product, PPCM, is a patented drug that demonstrates broad activity against various viruses and pathogens, positioning it as a significant advancement in antiviral therapies. This technology aims to provide effective treatment options for individuals affected by these infections.

In addition to their antiviral efforts, Yaso Therapeutics is committed to enhancing family planning options for women. The company recognizes the demand for non-hormonal contraceptives that are not only effective but also safe, affordable, and accessible. By focusing on these critical aspects, Yaso aims to deliver comprehensive contraceptive solutions that cater to women's health needs at every stage of their lives. This dual approach of addressing both antiviral treatment and contraceptive options underscores Yaso's commitment to improving women's health and well-being.

United States

Yaso is an early stage drug development company, dedicated to developing a line of drug  products for women and men that prevent sexually transmitted disease and unintended pregnancy.  We are a team of scientists and business people who have successfully developed, launched and grown women's reproductive health products.  We have the worldwide license for a unique polymeric drug with which we are currently developing several dosage forms for preclinical evaluation, leading to our IND.

Yaso Therapeutics

Company Details